Drug Discovery World

DECEMBER 20, 2023

The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines.

Clinical Research 52

Clinical Research Research Cardiology Dermatology 52

The Pharma Data

MARCH 13, 2022

Arena has previously indicated that it expected the results of the Phase 3 ELEVATE-UC trial of etrasimod in ulcerative colitis during the first quarter of 2022. In particular, we’re hopeful that we can accelerate clinical development of etrasimod successfully to have a positive impact on those living with these debilitating diseases.”.

Dermatology 52

Dermatology Cardiology Development Medicine 52

pharmaphorum

JANUARY 5, 2021

If they had also predicted that the second person to receive the vaccine out of trial would be a gentleman named William Shakespeare, they would certainly have been dismissed as a fantasist. “The real impact on submissions and approvals will be in 2021 and beyond, when the pandemic’s true impact on clinical trials becomes apparent”.

Sales 104

Sales Marketing Production Vaccination 104

The Pharma Data

SEPTEMBER 15, 2020

Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. A Phase 3 trial is ongoing. Protease Inhibitor Program. Rare Disease.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Gained an EU label update to include data for axial manifestations of psoriatic arthritis (PsA), from the Ph3b MAXIMISE trial. Adakveo sales reached USD 37 million. Cosentyx. .

Sales 40

Sales Medicine Production Manufacturing 40

XTalks

AUGUST 2, 2023

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. There was a record 34 approvals in major markets, and late-stage trials are commencing for medications including camizestrant, datopotamab deruxtecan and volrustomig.

Sales 98

Sales Manufacturing FDA Approval Life Science 98